All In Biotech

Drug Trial Radar · NCT07760961

Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia

Phase 2B Randomized, Placebo-Controlled, Double-Blind, Repeat Dose Parallel Study in Participants With Post-Bariatric Hypoglycemia to Determine the Effect of Mizagliflozin on Hypoglycemia

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Oct 20, 2026

Primary completion

Oct 2027

Study completion Jan 2028

Sponsor

Lead sponsor
Vogenx, Inc.Industry
Sponsor type
Industry
First posted
Aug 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

VGX-001-013 (EMERGE) is a Phase 2b study to evaluate an investigational new drug, mizagliflozin, for safety, tolerability and its ability to prevent low blood sugar in patients with post-bariatric hypoglycemia.

Conditions

  • Postbariatric Hypoglycemia

Interventions

  • Mizagliflozin 5 mgDrug

    5mg mizagliflozin capsules orally administered TID for 28 days

  • Mizagliflozin 10 mgDrug

    10mg mizagliflozin capsules orally administered TID for 28 days

  • PlaceboDrug

    Placebo capsules orally administered TID for 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of combined Level 2 (as measured by self-monitored blood glucose) and Level 3 hypoglycemic events (as measured by diary entry and adjudicated)Time frame: During the double-blind treatment period (approximately 28 days)

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Exalt Clinical Research

    Chula Vista, California · Recruiting

  • Stanford

    Palo Alto, California · Not yet recruiting

  • U Colorado- Anschutz Medical Campus

    Aurora, Colorado · Not yet recruiting

  • DM Clinical- Miami

    Doral, Florida · Not yet recruiting

  • Georgia Clinical Research

    Lawrenceville, Georgia · Not yet recruiting

  • Centricity Research

    Morehead City, North Carolina · Recruiting

  • Penn Medicine

    Philadelphia, Pennsylvania · Not yet recruiting

  • Vanderbilt Weight Loss Center

    Nashville, Tennessee · Not yet recruiting

  • DM Clinical- Irving

    Irving, Texas · Not yet recruiting

  • UT San Antonio

    San Antonio, Texas · Not yet recruiting

  • Texas Valley Clinical Research

    Weslaco, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.